| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
64,920,000 |
| Market
Cap: |
1.01(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$13.43 - $23.54 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 31.4 |
| Insider 6 Months : 31.4 |
| Insider 3/6 Months : 63.1 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating cancer therapies. Co.'s products include: Domvanalimab, which is an anti-TIGIT monoclonal antibody designed to promote sustained immune activation and tumor clearance; Etrumadenant, which is a dual A2a/A2b adenosine receptor antagonist, designed to inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes and myeloid cells; AB680, which is a potent and selective small-molecule CD73 inhibitor designed to provide differential benefits relative to monoclonal antibodies; and Zimberelimab, which is Co.'s anti-PD-1 antibody that Co. in-licensed to enable the development of its combination regimens.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
15,238,095 |
15,238,095 |
16,248,095 |
16,248,095 |
| Total Buy Value |
$319,999,995 |
$319,999,995 |
$339,452,595 |
$339,452,595 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
2 |
2 |
| Total Shares Sold |
110,657 |
141,439 |
237,875 |
329,459 |
| Total Sell Value |
$2,164,815 |
$2,731,452 |
$4,652,676 |
$7,003,905 |
| Total People Sold |
2 |
4 |
4 |
6 |
| Total Sell Transactions |
6 |
10 |
16 |
33 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rosen Terry J |
Chief Executive Officer |
• • – |
2018-03-19 |
4 |
A |
$0.00 |
$0 |
I/I |
2,475,654 |
3,818,078 |
|
- |
|
| Kaneko Yasunori |
Director |
– • – |
2018-03-19 |
4 |
A |
$0.00 |
$0 |
I/I |
791,392 |
96,948 |
|
- |
|
| Falberg Kathryn E |
Director |
– • – |
2018-03-19 |
4 |
B |
$15.00 |
$450,000 |
D/D |
30,000 |
80,504 |
2.39 |
- |
|
| Falberg Kathryn E |
Director |
– • – |
2018-03-19 |
4 |
A |
$0.00 |
$0 |
I/I |
17,106 |
17,106 |
|
- |
|
| Hadley Harbor Master Investors (cayman) Ii L.p. |
10% Owner |
– – • |
2018-03-19 |
4 |
A |
$0.00 |
$0 |
D/D |
1,496,813 |
1,496,813 |
|
- |
|
| Jaen Juan C. |
President |
• • – |
2018-03-19 |
4 |
B |
$15.00 |
$999,990 |
I/I |
66,666 |
2,734,240 |
2.66 |
- |
|
| Jaen Juan C. |
President |
• • – |
2018-03-19 |
4 |
A |
$0.00 |
$0 |
I/I |
2,175,150 |
2,667,574 |
|
- |
|
207 Records found
|
|
Page 9 of 9 |
|
|
0.08 (0.51%) 
